[go: up one dir, main page]

FR21C1005I2 - STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS - Google Patents

STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS

Info

Publication number
FR21C1005I2
FR21C1005I2 FR21C1005C FR21C1005C FR21C1005I2 FR 21C1005 I2 FR21C1005 I2 FR 21C1005I2 FR 21C1005 C FR21C1005 C FR 21C1005C FR 21C1005 C FR21C1005 C FR 21C1005C FR 21C1005 I2 FR21C1005 I2 FR 21C1005I2
Authority
FR
France
Prior art keywords
streptococcus pyogenes
dna fragments
corresponding dna
antigens
pyogenes antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1005C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Publication of FR21C1005I1 publication Critical patent/FR21C1005I1/fr
Application granted granted Critical
Publication of FR21C1005I2 publication Critical patent/FR21C1005I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)

Abstract

The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
FR21C1005C 2000-12-21 2021-02-04 STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS Active FR21C1005I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25694000P 2000-12-21 2000-12-21
PCT/CA2001/001853 WO2002050107A2 (en) 2000-12-21 2001-12-21 Streptococcus pyogenes antigens and corresponding dna fragments

Publications (2)

Publication Number Publication Date
FR21C1005I1 FR21C1005I1 (en) 2021-03-26
FR21C1005I2 true FR21C1005I2 (en) 2022-01-14

Family

ID=22974225

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1005C Active FR21C1005I2 (en) 2000-12-21 2021-02-04 STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS

Country Status (12)

Country Link
US (5) US7595057B2 (en)
EP (1) EP1343895B1 (en)
JP (1) JP4080876B2 (en)
AT (1) ATE398677T1 (en)
AU (2) AU2002216863B8 (en)
BE (1) BE2021C506I2 (en)
BR (1) BR0116704A (en)
CA (2) CA2789252C (en)
DE (1) DE60134494D1 (en)
ES (1) ES2307564T3 (en)
FR (1) FR21C1005I2 (en)
WO (1) WO2002050107A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1660660B1 (en) * 2003-08-15 2013-07-24 ID Biomedical Corporation of Quebec Pharmaceutical compositions for use in the treatment of Streptococcus Pyogenes infection
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
WO2024206953A2 (en) * 2023-03-29 2024-10-03 Taktos Therapeutics Inc. Ides variant proteins and methods of using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
ATE347600T1 (en) * 1998-02-20 2006-12-15 Id Biomedical Corp GROUP B-STREPTOCOCCUS ANTIGENS
GB9807890D0 (en) * 1998-04-09 1998-06-10 Actinova Ltd Peptides
JP2002531054A (en) 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド Nucleic acids and proteins from group B streptococci
ATE361365T1 (en) 1998-07-27 2007-05-15 Sanofi Pasteur Ltd STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
GB9828880D0 (en) * 1998-12-31 1999-02-17 Actinova Ltd Protein
US7074415B2 (en) * 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU7227001A (en) * 2000-07-06 2002-01-21 Shire Biochem Inc Streptococcus pyogenes antigens
AU2002210301A1 (en) * 2000-10-13 2002-04-22 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
MX357775B (en) * 2000-10-27 2018-07-20 J Craig Venter Inst Inc Nucleic acids and proteins from streptococcus groups a b.
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
DE60235223D1 (en) * 2001-02-21 2010-03-18 Id Biomedical Corp STREPTOCOCCUS PYOGENES POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS
IL158328A0 (en) * 2001-04-13 2004-05-12 Wyeth Corp Surface proteins of streptococcus pyogenes
ATE452191T1 (en) * 2001-07-06 2010-01-15 Id Biomedical Corp GROUP-B STREPTOCOCCUS ANTIGENS AND CORRESPONDING DNA FRAGMENTS
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) * 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
WO2004007725A1 (en) * 2002-07-15 2004-01-22 Id Biomedical Corporation Polypeptide of streptococcus pyogenes
EP1660660B1 (en) * 2003-08-15 2013-07-24 ID Biomedical Corporation of Quebec Pharmaceutical compositions for use in the treatment of Streptococcus Pyogenes infection
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2006256891B2 (en) * 2005-06-09 2011-08-04 Hansa Biopharma AB Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
US8323908B2 (en) * 2007-09-14 2012-12-04 Genovis Ab Method of assessing glycosylation state or functional quality of an IgG containing sample
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201316744D0 (en) * 2013-09-20 2013-11-06 Genovis Ab Method
GB201416849D0 (en) * 2014-09-24 2014-11-05 Genovis Ab Method

Also Published As

Publication number Publication date
US20100119507A1 (en) 2010-05-13
WO2002050107A2 (en) 2002-06-27
EP1343895A2 (en) 2003-09-17
AU2002216863B8 (en) 2008-03-20
AU2002216863B2 (en) 2008-02-28
US20150017684A1 (en) 2015-01-15
US7595057B2 (en) 2009-09-29
DE60134494D1 (en) 2008-07-31
ES2307564T9 (en) 2021-04-26
US20130136760A1 (en) 2013-05-30
CA2789252A1 (en) 2002-06-27
BR0116704A (en) 2003-12-23
BE2021C506I2 (en) 2021-05-31
JP4080876B2 (en) 2008-04-23
ES2307564T3 (en) 2008-12-01
JP2004524014A (en) 2004-08-12
CA2432525A1 (en) 2002-06-27
EP1343895B1 (en) 2008-06-18
CA2789252C (en) 2016-11-15
CA2432525C (en) 2012-11-27
US8821895B2 (en) 2014-09-02
US20160326221A1 (en) 2016-11-10
WO2002050107A3 (en) 2003-04-10
US20040097706A1 (en) 2004-05-20
US9340586B2 (en) 2016-05-17
AU1686302A (en) 2002-07-01
ATE398677T1 (en) 2008-07-15
US8298551B2 (en) 2012-10-30
FR21C1005I1 (en) 2021-03-26

Similar Documents

Publication Publication Date Title
FR21C1005I2 (en) STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
MY125202A (en) Vaccine
IL196900A (en) Autologous t-cell vaccine compositions
AU2001295671A1 (en) Pharmaceutical composition for immunisation against aids
ATE412750T1 (en) ANTIGEN FROM STREPTOCOCCUS PYOGENES
CY1117746T1 (en) Influenza hematopoietic antigens and corresponding DNA fragments
NO20030407D0 (en) Silicate-mediated synthesis of immorphous silicates and siloxanes and their use
WO2002060917A3 (en) Method to treat hemophilia
ATE321853T1 (en) HUMANIC PELLINO-POLYPEPTIDES
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
DE60235223D1 (en) STREPTOCOCCUS PYOGENES POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS
ATE349531T1 (en) ISOLATION AND CHARACTERIZATION OF THE CSA OPERON (ETEC-CS4 PILI) AND METHOD OF ITS APPLICATION
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
BR0111785A (en) Compositions and methods for treating candidiasis
DE60234772D1 (en) GROUP-B STREPTOCOCCUS ANTIGENIC AND CORRESPONDING DNA FRAGMENTS
DK0792347T3 (en) Methods for Preparation of Enhanced Antigenic Heliobacter sp. and vaccines comprising the same
WO2002088178A3 (en) Antigens of group b streptococcus and corresponding dna fragments
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses